< Back

NOW AVAILABLE

AK-FLUOR^®

Fluorescein Injection, USP

Long Grove Pharmaceuticals^® acquired the AK-FLUOR^® (Fluorescein Injection, USP) NDA in June 2023. AK-FLUOR is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature, and it is available as a sterile solution in the following concentrations:

• 10% (100mg/mL 5mL vials) 12 pack
• 25% (250mg/mL 2mL vials) 12 pack

Fluorescein Injection, USP is currently impacted by a supply shortage resulting from Akorn Pharmaceuticals’ exit from the U.S. market. To ensure the consistent availability of Fluorescein Injection, USP prior to its relaunch as a Long Grove Pharmaceuticals product, Long Grove Pharmaceuticals has reached a distribution agreement with the FDA Office of Drug Shortages through the Regulatory Discretion process. As a result, Long Grove Pharmaceuticals will make available the existing AK-FLUOR inventory manufactured by Akorn Pharmaceuticals in both 10% and 25% solutions.

For more details, see below.